ADAG - Adagene Inc Profile, Share Price, Market Analysis, Charts, Fundamentals

Company Name, Ticker, Industry, else..

Adagene Inc (NASDAQ: ADAG)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Price: $3.6095 $0.10

2.835%

Day's High:	$3.674999952316284	Week Perf:	-6.25 %
Day's Low:	$ 3.43	30 Day Perf:	-0.56 %
Volume (M):	52,247	52 Wk High:	$ 4.85
Volume (M$):	$ 0	52 Wk Avg:	$2.94
Open:	$3.58	52 Wk Low:	$1.30

ADAG Charts & Quotes

ADAG Charts & Quotes

Adagene Inc Company Profile

Company's Segments

Market Capitalization (Millions $)	213
Shares Outstanding (Millions)	59
Employees	128
Revenues (TTM) (Millions $)	8
Net Income (TTM) (Millions $)	-18
Cash Flow (TTM) (Millions $)	0
Capital Exp. (TTM) (Millions $)	0

Business Description

Adagene Inc. is a Cayman Islands holding company without direct operations. It conducts substantial business activities primarily through its Chinese subsidiary, Adagene (Suzhou) Limited, and its U.S. subsidiary, Adagene Incorporated. The company operates in both China and the United States and is subject to PRC regulations concerning data protection, cybersecurity, and securities activities, which may affect its operations and compliance obligations.

Company Address: 4F, Building C14, No. 218 Suzhou 215123
Company Phone Number: 87773632 Stock Exchange / Ticker: NASDAQ ADAG

Reports on Competition

Suppliers At a Glance

Stock Performances by Major Competitors

5 Days	Decrease / Increase

AZN	-4.25%
JNJ	-1.58%
LLY	-5.21%
MRK	-3.75%
NVS		0.78%
SNY	-2.61%
• View Complete Report

Adagene Inc News

Contract

Adagene and Third Arc Bio Forge Pioneering Alliance A New Era for Targeted Cancer Therapies

Published Thu, Nov 13 2025 12:44 PM UTC

In a strategic move that signals the ongoing evolution of cancer therapeutics, Adagene Inc. has announced a licensing agreement with Third Arc Bio, Inc. to develop two masked CD3 T cell engagers utilizing Adagene’s proprietary SAFEbody technology. The agreement, unveiled on November 13, 2025, marks a significant milestone not just for the companies involved, but also for t...

Product Service News

Adagene’s ADG126 Pioneering Cancer Treatment amid Financial Challenges,

Published Thu, Nov 7 2024 3:01 PM UTC

New Insights into Adagene s ADG126 and Implications for Financial HealthAt the recently concluded Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, Adagene Inc. presented groundbreaking data that highlights the significant promise of its investigational drug, ADG126 (Muzastotug), particularly in its ability to enhance the therapeutic index against various canc...

Clinical Study

Recent advancements in the treatment of advanced/metastatic microsatellite-stable (MSS) ...

Published Mon, Sep 16 2024 7:01 AM UTC

Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-Stable Colorectal Cancer: Insights from ESMO Congress Recent advancements in the treatment of advanced/metastatic microsatellite-stable (MSS) colorectal cancer (CRC) hold promising implications for improved patie...

Product Service News

Adagene's Clinical Collaboration Program Shows Promise in Treating Metastatic Colorectal Cancer

Published Fri, Feb 9 2024 11:00 AM UTC

Adagene, a leading biotechnology company, recently announced the progress and expansion of its clinical collaboration program for their promising drug, ADG126 (also known as muzastotug), in combination with KEYTRUDA (pembrolizumab), targeting patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC). This collaboration aims to further demonstrate the effic...

Clinical Study

Unveiling the Potential of ADG126: A New Era for MSS Colorectal Cancer Immunotherapy

Published Tue, Jan 16 2024 10:01 PM UTC

The treatment landscape for metastatic microsatellite-stable (MSS) colorectal cancer (CRC) has been evolving rapidly, with immunotherapy playing a significant role. In a recent study, Adagene presented interim results highlighting the potential of their novel therapy, masked anti-CTLA-4 SAFEbody ADG126 (muzastotug), in combination with pembrolizumab. This article aims to pro...

Fundamental Analysis

Valuation	Current
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	27.77
Price to Sales (Expected)	-
Price to Book	6.03
PEG (TTM)	-

Financial Strength	Current
Quick Ratio	8.25
Working Capital Ratio	8.56
Leverage Ratio (MRQ)	1.21
Total Debt to Equity	0.31
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Per Share	Current
Earnings (TTM)	-0.3 $
Revenues (TTM)	0.13 $
Cash Flow (TTM)	-
Cash	1.29 $
Book Value	0.6 $
Dividend (TTM)	0 $

Efficiency	Current
Revenue per Employee (TTM)	59,929
Net Income per Employee (TTM)	-137,574
Receivable Turnover Ratio (TTM)	-
Inventory Turnover Ratio (TTM)	-
Asset Turnover Ratio (TTM)	0.09

Profitability Ratios	Current
Gross Margin (MRQ)	-
Operating Margin (MRQ)	-279.48 %
Net Margin (MRQ)	-229.56 %
Net Cash Flow Margin (MRQ)	0 %
Effective Tax Rate (TTM)	-

Management Effectiveness	Current
Return On Assets (TTM)	-
Return On Investment (TTM)	-
Return On Equity (TTM)	-
Dividend Yield	-
Pay out Ratio (TTM)	-

Valuation
Price to Earnings PE Ratio (TTM)	-
Price to Earnings PE Ratio (Expected)	-
Price to Sales (TTM)	27.77
Price to Sales (Expected)	-
Price to Book	6.03
PEG (TTM)	-

Per Share
Earnings (TTM)	-0.3 $
Revenues (TTM)	0.13 $
Cash Flow (TTM)	-
Cash	1.29 $
Book Value	0.6 $
Dividend (TTM)	0 $

Financial Strength
Quick Ratio	8.25
Working Capital Ratio	8.56
Leverage Ratio (MRQ)	1.21
Total Debt to Equity	0.31
Interest Coverage (TTM)	-
Debt Coverage (TTM)	-

Efficiency
Revenue per Employee (TTM)	59,929
Net Income per Employee (TTM)	-137,574
Receivable Turnover Ratio (TTM)	-
Inventory Turnover Ratio (TTM)	-
Asset Turnover Ratio (TTM)	0.09

Profitability Ratio
Gross Margin (MRQ)	-
Operating Margin (MRQ)	-279.48 %
Net Margin (MRQ)	-229.56 %
Net Cash Flow Margin (MRQ)	0 %
Effective Tax Rate (TTM)	-

Management Effectiveness
Return On Assets (TTM)	-20.82 %
Return On Investment (TTM)	-28.57 %
Return On Equity (TTM)	-48.93 %
Dividend Yield	-
Pay out Ratio (TTM)	-

Adagene Inc's Segments

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.